Journal
MOLECULAR NEUROBIOLOGY
Volume 56, Issue 6, Pages 4023-4036Publisher
SPRINGER
DOI: 10.1007/s12035-018-1355-7
Keywords
A42 peptide; Human neural stem cells; Alzheimer's disease; Cell death; Cell fate specification; Cell proliferation
Categories
Funding
- MICINN-ISCIII [PI-10/00291, MPY1412/09]
- MINECO [SAF2015-71140-R]
- Comunidad de Madrid (NEUROSTEMCM consortium) [S2010/BMD-2336]
Ask authors/readers for more resources
Amyloid- 42 [A(1-42) (A42)] is one of the main A peptide isoforms found in amyloid plaques of brains with Alzheimer's disease (AD). Although A42 is associated with neurotoxicity, it might mediate several normal physiological processes during embryonic brain development and in the adult brain. However, due to the controversy that exists in the field, relatively little is known about its physiological function. In the present work, we have analyzed the effects of different concentrations of monomeric A42 on cell death, proliferation, and cell fate specification of human neural stem cells (hNSCs), specifically the hNS1 cell line, undergoing differentiation. Our results demonstrate that at higher concentrations (1M), A42 increases apoptotic cell death and DNA damage, indicating that prolonged exposure of hNS1 cells to higher concentrations of A42 is neurotoxic. However, at lower concentrations, A42 significantly promotes cell proliferation and glial cell specification of hNS1 cells by increasing the pool of proliferating glial precursors, without affecting neuronal differentiation, in a concentration-dependent manner. At the molecular level, these effects could be mediated, at least in part, by GSK3, whose expression is increased by treatment with A42 and whose inhibition prevents the glial specification induced by A42. Since the cellular and molecular effects are known to appear decades before the first clinical symptoms, these types of studies are important in discovering the underlying pathophysiological processes involved in the development of AD. This knowledge could then be used in diagnosing the disease at early stages and be applied to the development of new treatment options.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available